BioCryst Pharmaceuticals BCRX
$7.22 −$0.10 (-1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.10 -1.66%
Open$7.26
Prev close$7.32
Day range$7.15 – $7.39
Volume3.85M
Market cap$1.86B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$180.29M+13.1% YoY
Operating profit$53.33M+80.2% YoY
Net profit$37.92M+193.9% YoY
Diluted EPS$0.14+133.3% YoY
Free cash flow$32.75M-18.7% YoY
Operating cash flow$32.98M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin97.9%
Operating margin42.5%
Net margin-37.4%
Return on assets-69.3%
Current ratio2.71
Liabilities / assets167.2%
Cash & investments$375.00M
Total debt$781.01M
Net cash (debt)-$406.01M
Free cash flow / sales38.0%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $180.29M | $218.25M | $156.41M | $874.84M | $406.56M |
| Total Operating Revenue | $180.29M | $218.25M | $156.41M | $874.84M | $406.56M |
| Cost of Revenue | $1.57M | $3.84M | $5.38M | $19.08M | $9.52M |
| Gross Profit | $178.72M | $214.41M | $151.04M | $855.76M | $397.03M |
| Operating Expense | $125.39M | $115.95M | $154.87M | $514.77M | $136.65M |
| Selling and Admin Expenses | $67.18M | $63.98M | $94.55M | $348.65M | $95.78M |
| Research & Development | $58.21M | $51.97M | $60.32M | $166.13M | $40.87M |
| Operating Profit | $53.33M | $98.47M | -$3.84M | $340.99M | $260.39M |
| Net Non-Operating Interest Income (Expense) | -$18.11M | -$19.28M | -$17.52M | -$68.20M | -$11.25M |
| Non-Operating Interest Income | $3.07M | $2.43M | $2.26M | $10.67M | $2.89M |
| Non-Operating Interest Expense | $21.19M | $21.71M | $19.78M | $78.87M | $14.14M |
| Other Income (Expense) | $3.37M | $287,000.00 | -$699.45M | -$5.39M | -$1.12M |
| Gain on Sale of Security | $22,000.00 | $27,000.00 | -$225,000.00 | -$152,000.00 | -$125,000.00 |
| Special Income (Charges) | $0.00 | $0.00 | -$697.76M | -$17.33M | -$10.42M |
| Other Non-Operating Income (Expenses) | $3.35M | $260,000.00 | -$1.46M | $12.09M | $9.42M |
| Pretax Profit | $38.59M | $79.47M | -$720.81M | $267.39M | $248.02M |
| Tax | $669,000.00 | $1.08M | $1.00M | $3.53M | $2.17M |
| Net Profit | $37.92M | $78.40M | -$721.81M | $263.86M | $245.85M |
| Profit from Continuing Operations | $37.92M | $78.40M | -$721.81M | $263.86M | $245.85M |
| Net Income to Parent Company | $37.92M | $78.40M | -$721.81M | $263.86M | $245.85M |
| Net Income to Common Stockholders | $37.92M | $78.40M | -$721.81M | $263.86M | $245.85M |
| Basic EPS | $0.15 | $0.31 | -$2.98 | $1.26 | $1.17 |
| Diluted EPS | $0.14 | $0.30 | -$2.98 | $1.21 | $1.12 |
| -Less:Other Special Charges | – | – | $697.76M | $17.33M | $10.42M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $591.07M | $557.85M | $465.05M | $514.16M | $514.16M |
| Total Current Assets | $531.15M | $484.68M | $373.63M | $404.35M | $404.35M |
| Cash and Cash Equivalents & Short-Term Investments | $375.00M | $352.57M | $238.40M | $274.75M | $274.75M |
| -Cash and Cash Equivalents | $96.97M | $154.97M | $171.59M | $89.74M | $89.74M |
| -Short Term Investments | $278.03M | $197.60M | $66.81M | $185.01M | $185.01M |
| Receivables | $121.79M | $110.76M | $109.27M | $106.82M | $106.82M |
| -Accounts Receivable | $121.79M | $110.76M | $109.27M | $106.82M | $106.82M |
| Inventory | $13.74M | $6.06M | $5.99M | $5.40M | $5.40M |
| Restricted Cash | $518,000.00 | $479,000.00 | $854,000.00 | $201,000.00 | $201,000.00 |
| Other Current Assets | $20.11M | $14.82M | $19.11M | $17.18M | $17.18M |
| Total Non-Current Assets | $59.92M | $73.17M | $91.43M | $109.81M | $109.81M |
| Net PPE | $7.48M | $21.67M | $22.99M | $18.99M | $18.99M |
| -Gross PPE | $7.48M | $21.67M | $22.99M | $28.38M | $28.38M |
| Investments and Advances | $0.00 | $0.00 | $20.57M | $61.16M | $61.16M |
| Other Non-Current Assets | $52.44M | $51.50M | $47.87M | $29.66M | $29.66M |
| Total Liabilities | $988.45M | $1.01B | $1.02B | $633.31M | $633.31M |
| Total Current Liabilities | $195.83M | $208.85M | $195.39M | $196.07M | $196.07M |
| Payables | $14.58M | $11.46M | $10.96M | $24.79M | $24.79M |
| -Accounts Payable | $14.58M | $11.46M | $10.96M | $15.83M | $15.83M |
| Current Accrued Expenses | $110.69M | $121.90M | $119.40M | $39.96M | $39.96M |
| Short-Term Debt and Capital Lease Obligation | $3.44M | $3.00M | $3.09M | $1.63M | $1.63M |
| -Current Capital Lease Obligation | $3.44M | $3.00M | $3.09M | $1.63M | $1.63M |
| Current Deferred Liabilities | $10.54M | $12.32M | $5.41M | – | – |
| Other Current Liabilities | $56.58M | $60.17M | $56.53M | $52.20M | $52.20M |
| Total Non-Current Liabilities | $792.62M | $803.29M | $823.50M | $437.25M | $437.25M |
| Long Term Debt and Capital Lease Obligation | $781.01M | $789.83M | $814.67M | $437.25M | $437.25M |
| -Long Term Debt | $773.55M | $778.38M | $802.38M | $427.23M | $427.23M |
| -Long Term Capital Lease Obligation | $7.46M | $11.45M | $12.30M | $10.01M | $10.01M |
| Non-Current Deferred Liabilities | $11.61M | $13.46M | $8.83M | – | – |
| Total Equity | -$397.38M | -$454.29M | -$553.84M | -$119.15M | -$119.15M |
| Stockholders' Equity | -$397.38M | -$454.29M | -$553.84M | -$119.15M | -$119.15M |
| Capital Stock | $2.56M | $2.55M | $2.54M | $2.13M | $2.13M |
| -Common Stock | $2.56M | $2.55M | $2.54M | $2.13M | $2.13M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.71B | $1.69B | $1.67B | $1.38B | $1.38B |
| Retained Earnings | -$2.11B | -$2.15B | -$2.23B | -$1.51B | -$1.51B |
| Gains/Losses Not Affecting Retained Earnings | -$607,000.00 | -$528,000.00 | -$368,000.00 | $38,000.00 | $38,000.00 |
| -Accumulated Depreciation | – | – | – | -$9.39M | -$9.39M |
| -Other Payable | – | – | – | $8.96M | $8.96M |
| Current Provisions | – | – | – | $26.63M | $26.63M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $32.98M | $104.34M | -$61.79M | $347.37M | $291.96M |
| Net cash flow from continuing operations | $32.98M | $104.34M | -$61.79M | $347.37M | $291.96M |
| Net Income from Continuing Operations | $37.92M | $78.40M | -$721.81M | $263.86M | $245.85M |
| Gain/Loss from Continuing Operations | -$2.89M | $524,000.00 | $2.81M | $26.45M | $20.09M |
| Depreciation & Depletion & Amortization | $244,000.00 | $513,000.00 | $461,000.00 | $1.39M | $394,000.00 |
| Other Non-Cash Items | $11.97M | $13.75M | $711.88M | $30.85M | -$1.23M |
| Change in Working Capital | -$36.66M | -$3.11M | -$71.40M | -$56.90M | $4.23M |
| -Change in Receivables | -$11.03M | -$1.49M | -$474,000.00 | -$36.81M | -$15.49M |
| -Change in Inventory | -$6.87M | -$4.35M | -$4.85M | -$1.64M | -$515,000.00 |
| -Change in Prepaid Assets | -$5.92M | $4.43M | $3.53M | -$7.83M | -$1.94M |
| -Change in Payables and Accrued Expense | $9.66M | $5.07M | -$60.40M | $57.80M | $35.36M |
| -Change in Other Current Liabilities | -$18.86M | -$18.32M | -$8.47M | -$68.43M | -$13.19M |
| -Change In Other Working Capital | -$3.63M | $11.54M | -$749,000.00 | – | – |
| Net cash flow from investing | -$78.88M | -$110.15M | -$268.65M | -$13.69M | -$83.49M |
| Net Cash Flow from Continuing Investing Activities | -$78.88M | -$110.15M | -$268.65M | -$13.69M | -$83.49M |
| Net PPE Purchase and Sale | -$166,000.00 | -$209,000.00 | -$403,000.00 | -$2.47M | -$802,000.00 |
| Net Business Purchase and Sale | $0.00 | $0.00 | -$489.48M | -$6.18M | -$6.18M |
| Net Investment Purchase and Sale | -$78.71M | -$109.94M | $221.24M | -$5.59M | -$76.50M |
| Financing Cash Flow | -$12.08M | -$11.15M | $412.55M | -$349.93M | -$217.96M |
| Net Cash Flow from Continuing Financing Activities | -$12.08M | -$11.15M | $412.55M | -$349.93M | -$217.96M |
| Net Issuance Payments Of Debt | -$5.25M | -$361,000.00 | $399.66M | -$301.99M | -$184.58M |
| Net Common Stock Issuance | $49,000.00 | $44,000.00 | $33,000.00 | $59,000.00 | $23,000.00 |
| Proceeds from Stock Option Exercised | $4.24M | $6.20M | $19.48M | $9.12M | $657,000.00 |
| Net Other Financing Charges | -$11.12M | -$17.04M | -$6.62M | -$57.12M | -$34.06M |
| Ending Cash Balance | $98.42M | $156.38M | $173.38M | $91.34M | $91.34M |
| Net Change in Cash | -$57.97M | -$16.96M | $82.11M | -$16.26M | -$9.49M |
| Beginning Cash Balance | $156.38M | $173.38M | $91.34M | $106.32M | $86.06M |
| Effect of Exchange Rate Changes | $6,000.00 | -$35,000.00 | -$72,000.00 | $1.27M | -$72,000.00 |
| Free Cash Flow | $32.75M | $104.13M | -$62.19M | $344.90M | $291.16M |
| Net Other Investing Changes | – | – | – | $550,000.00 | $0.00 |
No comments yet — be the first to weigh in on BCRX.
Sign in to join the discussion.